News articles about Globus Medical (NYSE:GMED) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Globus Medical earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 46.2837006427879 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
GMED has been the topic of several recent analyst reports. BTIG Research set a $45.00 price target on Globus Medical and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. Morgan Stanley set a $53.00 price target on Globus Medical and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Zacks Investment Research raised Globus Medical from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research report on Monday, February 26th. ValuEngine raised Globus Medical from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $53.00 price target on shares of Globus Medical in a research report on Monday, March 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $49.57.
Shares of Globus Medical stock traded down $1.01 during midday trading on Monday, hitting $50.72. The stock had a trading volume of 546,935 shares, compared to its average volume of 664,857. Globus Medical has a one year low of $27.79 and a one year high of $52.18. The company has a market cap of $4,985.53, a P/E ratio of 46.11, a P/E/G ratio of 2.86 and a beta of 0.44.
Globus Medical (NYSE:GMED) last issued its earnings results on Wednesday, February 21st. The medical device company reported $0.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.35 by $0.03. Globus Medical had a return on equity of 13.93% and a net margin of 16.88%. The company had revenue of $176.03 million during the quarter, compared to the consensus estimate of $175.50 million. During the same period in the previous year, the company posted $0.31 EPS. The firm’s revenue for the quarter was up 16.1% compared to the same quarter last year. sell-side analysts forecast that Globus Medical will post 1.5 EPS for the current fiscal year.
WARNING: “Globus Medical (GMED) Earning Somewhat Favorable News Coverage, Report Finds” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://ledgergazette.com/2018/03/20/globus-medical-gmed-earning-somewhat-favorable-news-coverage-report-finds.html.
About Globus Medical
Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.